Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 15, 2024

Effect of PR Status on the Prognosis of Patients With Advanced ER-High HER2− Breast Cancer Receiving First-Line CDK4/6 Inhibitor Plus Endocrine Therapy

BMC Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

BMC Cancer
Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy
BMC Cancer 2024 Jul 17;24(1)850, L Jia, J Peng, N Sun, H Chen, Z Liu, W Zhao, Q Zhang, L Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading